Open AccessIs Reluctance to Share Alzheimer’s Disease Biomarker Status with a Study Partner a Barrier to Preclinical Trial Recruitment?
Author(s) -
Chelsea G. Cox,
Mary Morgan Ryan,
Daniel L. Gillen,
Joshua D. Grill
Publication year - 2020
Publication title -
the journal of prevention of alzheimer's disease/jpad
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.733
H-Index - 13
eISSN - 2426-0266
pISSN - 2274-5807
DOI - 10.14283/jpad.2020.36
Subject(s) - biomarker , logistic regression , confounding , medicine , clinical trial , test (biology) , informed consent , psychology , odds ratio , clinical psychology , alternative medicine , pathology , biology , paleontology , biochemistry , chemistry
Preclinical Alzheimer's disease clinical trials test candidate treatments in individuals with biomarker evidence but no cognitive impairment. Participants are required to co-enroll with a knowledgeable study partner, to whom biomarker information is disclosed.